Myriad Genetics announced that Brian Donnelly departed as Chief Commercial Officer effective September 16, 2026. The Board appointed Vishal Sikri, previously Senior Vice President of Product, to the role of Executive Vice President, Commercial, also effective September 16, 2026. Mr. Donnelly will remain a non-executive employee through September 21, 2026 to assist with the transition. The company reaffirmed its full-year 2026 financial guidance previously announced on July 30, 2026. Myriad Genetics operates in the molecular diagnostic testing and precision medicine industry.

Myriad Genetics reported second quarter 2026 revenue of $190.7 million, an 11% year-over-year decline driven by a 9% drop in average revenue per test and a 1% volume decrease. The company announced revised full-year 2026 financial guidance, lowering the revenue range to $770–$790 million from previous estimates and suspending Adjusted EBITDA guidance due to lower Prenatal Health volumes and payer friction pressures. Management initiated a strategic review and an efficiency program called Ascend, supported by a professional services firm, while continuing to expand its Cancer Care Continuum portfolio with new AI-enabled tests and coverage submissions. Myriad Genetics operates in the molecular diagnostic testing and precision medicine industry.

Daniel M. Skovronsky, M.D., Ph.D., resigned from the Board of Directors of Myriad Genetics, Inc. effective June 17, 2026. The resignation was not due to any disagreement with the company regarding its operations, policies, or practices. Myriad Genetics, Inc. is a biotechnology company providing genetic testing services.